BioCentury | Jun 28, 2019
Product Development

How Array stayed alive long enough to grow up

...neuroblastoma Ras viral (v-Ras) oncogene (NRAS)-mutant melanoma, as the clinical benefit in the Phase III NEMO...
BioCentury | Aug 16, 2018
Distillery Therapeutics

Cancer

...INDICATION: Lung cancer Cell culture studies suggest inhibiting IKK or its scaffold protein NEMO in combination...
...an IKK inhibitor, in preclinical testing to treat pancreatic cancer. TARGET/MARKER/PATHWAY: NF-κ-B essential modifier (NEMO; IKBKG...
...N.C. email: albert_baldwin@med.unc.edu Mark Zipkin University of North Carolina at Chapel Hill I-kappa B kinase (IKK) Mitochondrial complex 1 (MC-1) NF-kappa-B essential modifier (NEMO) (IKBKG) Serine/threonine...
BioCentury | May 12, 2017
Clinical News

Array planning melanoma combo NDA submission on Phase III data

...v-Ras) oncogene (NRAS)-mutant melanoma after concluding that the clinical benefit shown in the Phase III NEMO...
BioCentury | May 12, 2017
Clinical News

Array planning melanoma combo NDA submission on Phase III data

...v-Ras) oncogene (NRAS)-mutant melanoma after concluding that the clinical benefit shown in the Phase III NEMO...
BioCentury | May 11, 2017
Clinical News

Array gains on Phase III melanoma data

...v-Ras) oncogene (NRAS)-mutant melanoma after concluding that the clinical benefit shown in the Phase III NEMO...
BioCentury | Mar 21, 2017
Clinical News

Binimetinib regulatory update

...III NEMO trial “would not be found sufficient to support approval” in the indication. In NEMO...
BioCentury | Mar 20, 2017
Company News

Array withdraws binimetinib NDA

...and communications" with FDA, it concluded that the clinical benefit shown in the Phase III NEMO...
...in the indication. In December 2015, Array said binimetinib improved progression-free survival over dacarbazine, meeting NEMO's...
BioCentury | Sep 1, 2016
Company News

FDA accepts Array's binimetinib NDA

...and MEK2 . Last year, binimetinib met the primary endpoint in the Phase III NEMO...
BioCentury | Apr 2, 2016
Clinical News

Array discontinues ovarian cancer Phase III

...affect the Phase III NEMO or COLUMBUS studies of binimetinib to treat melanoma. Binimetinib met NEMO's...
BioCentury | Dec 21, 2015
Clinical News

Binimetinib: Phase III data

...The open-label, international Phase III NEMO trial in 402 patients with unresectable or metastatic NRAS mutation-positive...
Items per page:
1 - 10 of 23